eIF4E Interaction Status Prediction for BRAF Inhibitor Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly those targeting the MAPK pathway, face challenges with primary resistance and secondary resistance mechanisms, leading to limited efficacy and short-term responses in patients, necessitating a more precise method to assess tumor sensitivity to therapeutic agents.
Innovation Solution
The method involves evaluating the status of the eIF4E interaction with its partners eIF4G or 4EBP1 in cancer cells, using the Cap-ON and Cap-OFF complex ratios to determine tumor sensitivity or resistance to antitumoral agents, particularly inhibitors of the MAPK or PI3K pathways, through assays like proximity ligation and CAP-binding assays, and employing compensatory molecules like hippuristanol or silvestrol to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If targeted therapy with BRAF inhibitors (vemurafenib) is used to treat melanoma patients with BRAF V600 mutations, then early objective response rate is improved (more than 50%), but duration of response deteriorates (short duration, relapse after 6-12 months)
Solution Approach 1:
The patent applies preliminary action by assessing the eIF4E interaction status (Cap-ON/Cap-OFF complex ratio) before initiating BRAF inhibitor therapy. This pre-treatment evaluation predicts which patients are likely to develop resistance, allowing for proactive intervention strategies such as combining BRAF inhibitors with eIF4E inhibitors or alternative therapies in patients with high Cap-ON ratios, thereby preventing treatment failure before it occurs.
2Ease of operation
If conventional BRAF inhibitor monotherapy is administered, then treatment simplicity is maintained, but resistance mechanisms (both primary and secondary) develop leading to treatment failure
Solution Approach 1:
The patent implements feedback by using the Cap-ON/Cap-OFF complex ratio as a predictive biomarker to guide therapy selection. This feedback mechanism allows clinicians to adjust treatment strategies based on the molecular profile of the tumor, moving from empirical monotherapy to personalized combination therapy or alternative approaches when high Cap-ON ratios indicate likely resistance to BRAF inhibitors.
3Measurement precision
If eIF4E interaction status is evaluated using proximity ligation or CAP-binding assays, then treatment prediction accuracy is improved, but diagnostic complexity and cost increase
Solution Approach 1:
The patent uses the Cap-ON/Cap-OFF complex ratio as an intermediary biomarker that translates complex molecular interactions into a simple, quantifiable metric. By measuring the interaction status of eIF4E with eIF4G versus 4EBP1, the assay provides a straightforward predictive value that can be integrated into clinical decision-making without requiring complex interpretation of multiple molecular parameters.
Data Source
AI summary
The present invention relates to a method of evaluating the sensitivity or resistance of a cancer cell to an antitumoral therapeutic treatment. It further relates to the treatment of a cancer with an inhibitor of the eiF4F complex used for the sensitisation of said cancer to an antitumoral therapeutic treatment.